Management
Stephen M. Simes (President and Chief Executive Officer)
Stephen M. Simes has served as our Vice Chairman, President and a director of our company since January 1998 and Chief Executive Officer since March 1998.
From October 1994 to January 1997, Mr. Simes was President, Chief Executive Officer and a Director of Unimed Pharmaceuticals, Inc., (currently a wholly owned subsidiary of Abbott Laboratories) a company with a product focus on infectious diseases, AIDS, endocrinology and oncology. From 1989 to 1993, Mr. Simes was Chairman, President and Chief Executive Officer of Gynex Pharmaceuticals, Inc., a company which concentrated on the AIDS, endocrinology, urology and growth disorders markets. In 1993, Gynex was acquired by Savient Pharmaceuticals Inc. (formerly Bio-Technology General Corp.), and from 1993 to 1994, Mr. Simes served as Senior Vice President and director of Savient Pharmaceuticals Inc. Mr. Simes's career in the pharmaceutical industry started in 1974 with G.D. Searle & Co. (now a part of Pfizer Inc.). Mr. Simes currently serves as our designee on the board of directors of Ceregene, Inc., a privately held biotechnology company focused on the treatment of major neurodegenerative disorders using the delivery of nervous system growth factors. As a result of our merger with Cell Genesys, we acquired an investment equivalent to approximately 16 percent of the total equity of Ceregene, and by virtue of such ownership, we have the right to designate one member of Ceregene's board of directors. We believe Mr. Simes's qualifications to sit on the Board of Directors of our company include his depth of knowledge of our company and its day to day operations and the pharmaceutical industry due to his service as our chief executive officer and previous officer positions with other pharmaceutical companies.
Phillip B. Donenberg, CPA (Chief Financial Officer, Treasurer and Secretary)
Phillip B. Donenberg, CPA, has served as our Chief Financial Officer, Treasurer and Secretary since July 1998.
Before joining our company, Mr. Donenberg was Controller of Unimed Pharmaceuticals, Inc. (currently a wholly owned subsidiary of Abbott Laboratories) from January 1995 to July 1998. Prior to Unimed Pharmaceuticals, Inc., Mr. Donenberg held similar positions with other pharmaceutical companies, including Gynex Pharmaceuticals, Inc. (currently Savient Pharmaceuticals, Inc.), Applied NeuroSolutions, Inc. (formerly Molecular Geriatrics Corporation) and Xtramedics, Inc.
Bill Milling (Controller and Senior Director of Operations)
Bill Milling, CPA, has served as our Controller and Senior Director of Operations since October, 2004.
Before joining our company, Mr. Milling was the Controller of Dor BioPharma from March 2002 to September 2004. From 1994 to 2002, Mr. Milling was with CCH, Inc. where he held various financial and systems positions of increasing responsibility. Mr. Milling holds a Bachelor of Science degree in Accountancy.
Michael C. Snabes (Vice President of Clinical Development)
Michael C. Snabes M.D., Ph.D. has served as our Vice President of Clinical Development since April, 2008. Dr. Snabes has served as a medical consultant to BioSante on clinical and regulatory matters since November, 2005. Dr. Snabes is a board certified reproductive endocrinologist, as well as holding a Ph.D. in physiology and reproductive endocrinology.
Before joining our company, Dr. Snabes was an Associate Professor in the Section of Reproductive Endocrinology and Infertility in the Department of Obstetrics and Gynecology at The University of Chicago Pritzker School of Medicine. From 2003 to 2004, Dr. Snabes served as Medical Advisor in Clinical Research and Development in Inflammation, Arthritis, and Pain at Pfizer, Inc. and from 1999-2003 in the same position at Pharmacia, Inc. where he worked on the successful development of the COX-2 inhibitors, Celebrex and Bextra. From 1997 to 1999, Dr. Snabes served as Associate Director in Clinical Research in Women's Health at Searle/Monsanto. Dr. Snabes is an elected Fellow of the American College of Obstetrics and Gynecology, the American College of Surgeons and the American College of Endocrinology. Dr. Snabes is the author of more than 135 publications and abstracts.
Jeffrey W. Winkelman, Ph.D., J.D. (Vice President, Oncology Programs)
Jeffrey W. Winkelman, Ph.D., J.D. has served as our Vice President, Oncology Programs since January 2010, and as a consultant to the Company since October 2009.
Before joining our Company, Dr. Winkelman was President, IP Solutions, an independent biotechnology consulting firm. From December 2004 until October 2008, Dr. Winkelman was the Vice President, Intellectual Property at Cell Genesys, Inc. From 1994 until 2004, Dr. Winkelman held a number of other similar positions with other biotechnology companies, including Sibia Neurosciences, Inc., Advanced Tissue Sciences, Inc. and Elitra Pharmaceuticals. Dr. Winkelman was also an associate at the IP law firm of Brown, Martin, Haller & McClain.
